An observational study in Colorectal Liver Metastasis, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Memorial Sloan Kettering Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center — 13 open to participants now, 27 under way, 1 of them phase 3. Neoplasm Metastasis · Memorial Sloan Kettering Cancer Center.
Among the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center, this one is one of 3 that started in 2015, is one of 6 observational ones, reaches primary completion later than 5 of the 26 other live ones, and was the 32nd registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →13 of the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 6–49
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 22+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 25 · Phase 3 3
First in 1998; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 219 is above the median of 137 across 561 observational studies indexed under Neoplasm Metastasis.
Median enrollment 37 across the 50 interventional studies, 224 across the 6 observational. Of the 34 that completed or were terminated, 15 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
18 of the studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04143516Phase 3Memorial Sloan Kettering Cancer CenterTissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment | 2027-10 |
| NCT05117931Memorial Sloan Kettering Cancer CenterA Study of Amivantamab in People With Esophagogastric Cancer | 2026-11 |
| NCT01470105Memorial Sloan Kettering Cancer CenterImproving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases | 2026-11 |
| NCT03794635Memorial Sloan Kettering Cancer CenterAn Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer | 2026-12 |
| NCT02399995Memorial Sloan Kettering Cancer CenterHealth Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time | 2027-03 |
Add all 18 to your calendar (.ics) → With an account.
Among the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to learn more about health related quality of life factors in people having surgery for colorectal liver metastasis. The investigators will look at how these factors may change over time. The information gained from this study will help the investigators to understand the long-term effects that cancer treatments have on the health related quality of life of patients. This information is of high value and will help doctors talk to patients about the possible effects of their operations. While many patients live a long time after such operations, the studies that have been done do not tell the full story of what patients go through after surgery. This study will help us to understand cancer treatment from the patient's perspective. It will also help cancer patients make better decisions about their treatment options and will help them know what to expect after the operation.
All patients scheduled to undergo liver resection who meet the established criteria will be approached for participation in this study during their preoperative visit. Should patients not undergo their liver resection surgery within 30 days of consent they will be excluded and replaced. Patients undergoing a two stage resection will have their time point frozen for up to six months after their initial surgery. If the time before the second stage of their resection exceeds six months, these patients will be excluded and replaced. The time point will restart at the completion of the second time point. If the patient has an incomplete resection without mention of a second stage resection, the patient will be made ineligible, taken off study, and replaced.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: HRQoL questionnaires.
Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator: * Baseline sociodemographic and clinical variable data sheet (RSA) * EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS * Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit: * EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy: * EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS * Post surgical follow up disease status and treatment assessment questionnaire * At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone.
changes in the quality of life (QoL)
in patients at high risk of recurrence undergoing hepatectomy to assess health related quality of life (HRQoL) using the EORTC QLQ-C30, QLQ-LMC21 and the EuroQol EQ-5D-5L, in patients at high risk of recurrence undergoing hepatectomy for colorectal liver metastasis and to evaluate global and disease specific changes over time.
Time frame: 3 years
Started Mar 2015 (actual). Primary completion is estimated for Mar 2027, 144 months after the start.
Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 144 months is above that.
Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →